ARTIVION INC
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
AORT$20.47-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Net cash flows from operating activities: | ||
| Net income (loss) | $3,124 | $(26,715) |
| Adjustments to reconcile net income (loss) to net cash from operating activities: | ||
| Depreciation and amortization | 17,910 | 17,260 |
| Change in fair value of contingent consideration | (12,170) | 21,900 |
| Non-cash compensation | 11,499 | 10,466 |
| Non-cash lease expense | 5,860 | 5,467 |
| Deferred income taxes | (4,187) | (7,250) |
| Non-cash debt extinguishment expense | 3,669 | — |
| Write-down of inventories and deferred preservation costs | 2,911 | 3,726 |
| Fair value adjustment of Endospan agreements | (195) | 5,000 |
| Gain from sale of non-financial assets | — | (14,250) |
| Other | 1,818 | 2,325 |
| Changes in operating assets and liabilities: | ||
| Accounts payable, accrued expenses, and other liabilities | (5,237) | 412 |
| Inventories and deferred preservation costs | (4,791) | (10,592) |
| Prepaid expenses and other assets | (4,758) | (527) |
| Receivables | (3,356) | 765 |
| Net cash flows provided by operating activities | 12,097 | 7,987 |
| Net cash flows from investing activities: | ||
| Capital expenditures | (9,763) | (7,083) |
| Payments for Endospan agreements | (7,000) | (5,000) |
| Proceeds from sale of non-financial assets, net | — | 14,250 |
| Net cash flows (used in) provided by investing activities | (16,763) | 2,167 |
| Net cash flows from financing activities: | ||
| Proceeds from issuance of debt | 190,000 | — |
| Proceeds from revolving credit facility | 30,000 | — |
| Proceeds from exercise of stock options and issuance of common stock | 5,285 | 3,467 |
| Proceeds from financing insurance premiums | — | 3,558 |
| Repayment of debt | (211,765) | (2,063) |
| Payment of debt issuance costs | (10,044) | — |
| Principal payments on short-term notes payable | (1,027) | (1,522) |
| Other | (420) | (945) |
| Net cash flows provided by financing activities | 2,029 | 2,495 |
| Effect of exchange rate changes on cash and cash equivalents | (130) | 1,481 |
| (Decrease) increase in cash and cash equivalents | (2,767) | 14,130 |
| Cash and cash equivalents beginning of period | 58,940 | 39,351 |
| Cash and cash equivalents end of period | $56,173 | $53,481 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.